Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights
Provided By GlobeNewswire
Last update: Mar 20, 2025
– Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical trial of SENTI-202 maintaining remission –
Read more at globenewswire.com1.31
-0.1 (-7.42%)
Find more stocks in the Stock Screener
SNTI Latest News and Analysis
